The HCPLive Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for C difficile, IBS and IBD, Crohn's disease, and more.
May 31st 2024
Using available literature, the review assesses our current understanding of AATD, emerging biomarkers, and the future of drug development.
Ulcerative Colitis Patients in Remission Have Recovered Gut Microbiota
Patients in long-remission also presented with fecal bacterial composition that was similar to what was found in the healthy control group and there was a positive correlation between Akkermansia muciniphila abundance and time in remission.
Fasting, Food Exclusions Common for Patients With Inflammatory Bowel Disease
Disease activity and treatment with a small-molecule or an investigation drug were independently linked to an exclusion diet, while a history of stenosis and active disease were associated with fasting.
Risk of Hospitalization for Patients With HE
April 19th 2023Drs Arun Jesudian and James Williams share thoughts on patients with hepatic encephalopathy who are at risk of hospitalization, poorer patient and economic outcomes associated with readmission rates, and the impact of hepatic encephalopathy on quality of life.
Obefazimod Results in Clinical Remission for Majority of Ulcerative Colitis Patients
The results show 52.5% of patients achieved clinical remission at week 96, while 59.0% saw endoscopic improvement, 35.9% achieved endoscopic remission, and 70.5% achieved a clinical response.
High-Dose VE303 Shows Promise Treating Patients at Risk of Recurrent CDI
The rate of CDI recurrence through week 9 using the efficacy analysis 3 definition was 13.8% for the high-dose VE303 group, compared to 37% for the low-dose VE303 group and 45.5% for the placebo group.
Bidirectional Montreal Classification Better Captures Crohn’s Disease Complications
Using the bidirectional Montreal classification system, which accounts for disease regression, showed that 90% of patients exhibited inflammatory disease behavior at 5 years, compared to 58% if the hierarchical, unidirectional Montreal classification system was implemented.
New Study Explores Racial Disparity in HBV Treatment Initiation
The cumulative probabilities of treatment initiation after meeting the criteria was not significantly different between the different racial groups and the incidence of major adverse liver outcomes was 0.1 per 100 person-years and did not differ by race.
Weekly Folic Acid Supplementation Helps Maintain Folate Levels in IBD Patients
At the 6 month follow-up visit, all participants had stable folic acid levels without macrocytic anemia and the monthly questionnaires showed no increase in symptoms or adverse events reported.
Revolo Readying Data on Allergen Sensitivity Drug
The treatment is a first-in-class peptide derived from mTB Chaperonin 60.1 that is often involved in resetting the immune system. The treatment is being evaluated in patients with eosinophilic esophagitis and allergen sensitivity.